The left and right ventricle of a patient with a R723G mutation of the beta-myosin heavy chain and severe hypertrophic cardiomyopathy show no differences in the expression of myosin mRNA

Cardiology Journal

Volumn 17, Issue 5, 2010, Pages 518-522

  Borchert, Bianca ^a   Tripathi, Snigdha ^a   Francino, Antonio ^b   Navarro Lopez, Francisco ^b   Kraft, Theresia ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Hyperthropic cardiomyopathy; Hypertrophy; Molecular biology

Indexed keywords

AMIODARONE; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; ENALAPRIL; FUROSEMIDE; MESSENGER RNA; MYOSIN HEAVY CHAIN BETA; VERAPAMIL;

ADULT; ARTICLE; CASE REPORT; DEFIBRILLATION; DIASTOLIC DYSFUNCTION; ECHOCARDIOGRAPHY; FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; GENE EXPRESSION; GENE MUTATION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE BIOPSY; HEART RIGHT VENTRICLE; HEART TRANSPLANTATION; HEART VENTRICLE TACHYCARDIA; HUMAN; LOW DRUG DOSE; LUNG EDEMA; MALE; POLYMERASE CHAIN REACTION; SYNCOPE; TRANSIENT ISCHEMIC ATTACK;

CARDIOMYOPATHY, HYPERTROPHIC, FAMILIAL; HEART TRANSPLANTATION; HEART VENTRICLES; HUMANS; MALE; MIDDLE AGED; MYOSIN HEAVY CHAINS; PHENOTYPE; POINT MUTATION; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; VENTRICULAR REMODELING;

EID: 77957944693     PISSN: 18975593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Harris KM, Spirito P, Maron MS et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end--stage phase of hypertrophic cardiomyopathy. Circulation, 2006; 114: 216-225.
2. Marian A, Roberts R. The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol, 2001; 33: 655-670.
3. Enjuto M, Francino A, Navarro-Lopez F, Viles D, Pare' JC, Ballesta AM. Malignant hypertrophic cardiomyopathy caused by the Arg723Gly mutation in beta-myosin heavy chain gene. J Mol Cell Cardiol, 2000; 32: 2307-2313.
4. Tripathi S, Becker E, Dunda S et al. Familial hypertrophic cardiomyopathy: Deviation from a 1:1 ratio between mutated and wild type beta-MHC in muscle biopsies from patients with myosin head domain mutations. Clin Res Cardiol, 2009; 98: suppl. 1.
5. Becker E, Navarro-López F, Francino A, Brenner B, Kraft T. Quantification of mutant versus wild-type myosin in human muscle biopsies using nano-LC/ESI-MS. Anal Chem, 2007; 79: 9531-9538.
6. Nier V, Schultz I, Brenner B, Forssmann WG, Raida M. Variability in the ratio of mutant to wild type myosin heavy chain present in the soleus muscle of patients with familial hypertrophic cardiomyopathy. A new approach for the quantification of mutant to wild type protein. FEBS, 1999; 461: 246-252.
7. Seebohm B, Matinmehr F, Köhler J et al. Cardiomyopathy mutations reveal variable region of myosin converter as major element of cross-bridge compliance. Biophys J, 2009; 97: 806-824.
8. Kirschner SE, Becker E, Antognozzi M et al. Hypertrophic cardiomyopathy- related beta-myosin mutations cause highly variable calcium sensitivity with functional imbalances among individual muscle cells. Am J Physiol Heart Circ Physiol, 2005; 288: H1242-H1251.
9. Ashrafian H, Watkins H. Reviews of translational medicine and genomics in cardiovascular disease: New disease taxonomy and therapeutic Implications cardiomyopathies: Therapeutics based on molecular phenotype. J Am Coll Cardiol, 2007; 49: 1251-1264.
10. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rew, 2006; 7: 589-600.
11. Crilley JG, Boehm EA, Blair E et al. Hypertrophic cardiomyopathy cue to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol, 2003; 41: 1776-1782.
12. Deb SJ, Schaff HV, Dearani JA, Nishimura RA, Ommen SR. Septal myectomy results in regression of left ventricular hypertrophy in patients with hypertrophic obstructive cardiomyopathy. Ann Thorac Surg, 2004; 78: 2118-2122.
13. Maron MS, Hauser TH, Dubrow E et al. Right ventricular involvement in hypertrophic cardiomyopathy. Am J Cardiol, 2007; 100: 1293-1298.
14. Lombardi R, Dong J, Rodriguez G et al. Genetic fate mapping identifies second heart field progenitor cells as a source of adipocytes in arrhythmogenic right ventricular cardiomyopathy. Circ Res, 2009; 104: 1076-1084.
15. Kelly RG. Building the right ventricle. Circ Res, 2007; 100: 943-945.